EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

Rhea-AI Summary

EyePoint (EYPT) reported a third-quarter net loss of $95.6 million while prioritizing DURAVYU development for diabetic macular edema (DME). Revenue fell to $0.8 million from $1.0 million a year earlier; loss per share widened to $1.07 from $0.85. Operating expenses rose to $97.6 million from $63.0 million.

Both Phase 3 wet age-related macular degeneration trials missed their primary vision endpoints. EyePoint plans to conclude that program early, while allowing additional patients to finish year two for DME safety data. The fully enrolled COMO and CAPRI DME trials include over 550 patients, with results expected early in Q4 2027.

An approximately 53% workforce reduction and operational adjustments are expected to save approximately $30 million annually. Cash and securities totaled $118 million. Including $10 million raised after quarter-end and anticipated adjustments, EyePoint expects funding into late Q3 2027.

15 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

3 major · 17 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPost-quarter-end equity financing raised $10 million through the at-the-market facility. 33% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.COMO and CAPRI completed enrollment with over 550 patients; results are anticipated early in Q4 2027.
• Moderate pointVERONA's DURAVYU 2.7 mg arm met its primary endpoint in Phase 2 DME testing.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Operational prioritization is expected to generate approximately $30 million in estimated annualized savings.
• Minor pointVERONA showed +7.1 letters in best-corrected vision and a 76-micron retinal thickness reduction at Week 24.

10 minor points

• Minor pointVERONA patients remaining supplement-free through Week 24 reached 73%, versus 50% with aflibercept.
• Minor pointLUGANO treatment burden fell 42% versus on-label aflibercept, with nominal p-value <0.0001.
• Minor pointLUGANO eyes were 54% supplement-free; 79% received zero or one supplement up to Week 56.
• Minor pointLUCIA treatment burden fell 38% versus on-label aflibercept, with nominal p-value <0.0001.
• Minor pointLUCIA eyes were 52% supplement-free; 71% received zero or one supplement up to Week 56.
• Minor pointPooled supplement-free patients, greater than 50% of both trials, showed statistical non-inferiority in mean best-corrected vision change.
• Minor pointRepeat-dosing safety observations included no retinal vasculitis, insert migration, anterior chamber opacities or free-floating drug particles.
• Minor pointThird-quarter cost of sales declined to $523,000 from $721,000 a year earlier.
• Minor pointNine-month cost of sales declined to $1.056 million from $1.691 million a year earlier.
• Minor pointNine-month sales and marketing expenses declined to $65,000 from $96,000 a year earlier.

Negative

• Major pointLUGANO and LUCIA missed primary endpoints for vision non-inferiority versus on-label 2 mg aflibercept in full analysis populations.
• Major pointThird-quarter net loss widened to $95.612 million, or $1.07 per share, from $59.732 million, or $0.85.
• Major pointPost-quarter-end at-the-market equity issuance adds dilution for existing shareholders.
• Moderate point. Forward-looking: it has not happened yet and may not happen.The wet AMD program will conclude before full second-year completion, with additional patients retained for DME safety data.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Strategic prioritization entails an approximately 53% workforce reduction.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Expected funding lasts into late Q3 2027, including post-quarter-end financing and anticipated operational adjustments.
• Moderate pointCash and securities declined to $118 million at September 30, 2026, from $306 million at December 31, 2025.
• Moderate pointNine-month revenue fell to $1.959 million from $30.751 million a year earlier.

9 minor points

• Minor pointThird-quarter revenue fell to $756,000 from $966,000 a year earlier.
• Minor pointThird-quarter research and development expenses rose to $81.670 million from $47.754 million a year earlier.
• Minor pointThird-quarter general and administrative expenses rose to $15.409 million from $14.490 million a year earlier.
• Minor pointThird-quarter sales and marketing expenses rose to $31,000 from $26,000 a year earlier.
• Minor pointThird-quarter net other income fell to $1.265 million from $2.293 million a year earlier.
• Minor pointNine-month net loss widened to $274.914 million, or $3.15 per share, from $164.353 million, or $2.35.
• Minor pointNine-month research and development expenses rose to $237.427 million from $161.825 million a year earlier.
• Minor pointNine-month general and administrative expenses rose to $44.894 million from $40.228 million a year earlier.
• Minor pointNine-month net other income fell to $6.519 million from $8.829 million a year earlier.

News Explained

EyePoint reports it raised $10 million after quarter-end through its at-the-market equity facility; that structure sells new shares gradually at prevailing prices, bringing cash to the company while potentially diluting existing common holders.

Argus 15 min delay 17 alerts

-7.57% vs previous close $0.3296 last price 1.4x rel. volume Open Argus

Details

Market move: EYPT -7.57% vs previous close. 3Q26 earnings report

-9.4% Trough in 27 min

$0.31 – $0.37 Day Range

$28.42M Mkt Cap at Last Price

On Nov 12, the day this news came out, the latest delayed price for EYPT is 7.57% below the previous close. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $0.33.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Operating expenses: $97.6 million vs. $63.0 million Net loss: $95.6 million vs. $59.7 million Cash and marketable securities: $118 million vs. $306 million +5 more

Operating expenses

$97.6 million vs. $63.0 million

Q3 2026 vs. Q3 2025

Net loss

$95.6 million vs. $59.7 million

Q3 2026 vs. Q3 2025

Cash and marketable securities

$118 million vs. $306 million

September 30, 2026 vs. December 31, 2025

Annualized savings

$30 million

Expected from strategic prioritization and operational adjustments

Capital raised

$10 million

Raised after quarter-end through the at-the-market equity facility

Cash runway

Into late third quarter of 2027

Company outlook incorporating cash, post-quarter capital raised, and anticipated operational adjustments

Phase 3 DME enrollment

Over 550 patients

COMO and CAPRI trials; fully enrolled

DME topline data timing

Early fourth quarter of 2027

COMO and CAPRI Phase 3 trials

Previous Earnings Reports

1 past event · Latest: Aug 05

Same Type 1 event

1. Aug 05

   2Q26 earnings

   24h Move

   +5.0%

   Reported a $94.5 million net loss and $180 million in cash as of June 30.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

vegf, bcva, cst, non-inferiority, +1 more

5 terms

vegf medical

"vascular endothelial growth factor (VEGF)"

Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels, like a fertilizer prompts plants to sprout. It matters to investors because drugs that block or mimic VEGF can dramatically change outcomes for cancers and eye diseases, making them major drivers of clinical trial results, regulatory approvals, market value and future revenue potential for biopharma companies.

bcva medical

"best-corrected visual acuity (BCVA)"

Best corrected visual acuity (BCVA) is the sharpest level of vision a person can achieve when using the optimal prescription lenses during an eye exam, measured by reading standardized letters on a chart. Investors care because BCVA is a common, standardized clinical endpoint in eye‑disease trials and regulatory reviews; improvements in BCVA are used like a speedometer to gauge how well a treatment works and therefore influence a product’s market potential and valuation.

cst medical

"central subfield thickness (CST)"

CST is a time-zone abbreviation used to stamp when an event, filing or market notice occurred; it tells readers which local clock is being referenced. Because the same letters can mean different regional zones (for example, North American Central Standard Time or China Standard Time), investors should check the context or the listed UTC offset to know the exact moment an announcement was made—timing affects trading, deadlines and market reactions.

non-inferiority medical

"The identical non-inferiority trials versus an on-label aflibercept control"

A non-inferiority trial is a type of clinical test designed to show a new treatment is not meaningfully worse than an existing standard by more than a pre-set, acceptable amount. Think of it like proving a new smartphone model has battery life close enough to the leading model while offering other advantages; for investors, a successful non-inferiority result can clear the way to regulatory approval and market uptake even when the new option isn’t superior in headline effectiveness.

at-the-market financial

"pursuant to our “at-the-market” equity facility"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Organizational focus on DURAVYU^TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 –

– DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis –

– Strategic prioritization expected to generate $30 million in annualized savings –

– $118 million in cash, cash equivalents and short-term investments, as of September 30, 2026 –

WATERTOWN, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate developments.

“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “Our conviction in the DME program is further grounded in the positive Phase 2 VERONA trial results, the multi-MOA activity for DURAVYU addressing the distinct biology of DME driven by both inflammatory pathways as well as vascular endothelial growth factor (VEGF), the substantial clinical experience established with DURAVYU, and the opportunity to evaluate the program in two fully enrolled, well-controlled pivotal trials within a year.”

In the Phase 2 VERONA clinical trial in DME, DURAVYU 2.7 mg met the primary endpoint and demonstrated an early and sustained improvement in vision and anatomical control, including a +7.1-letter improvement in best-corrected visual acuity (BCVA) and a 76-micron reduction in central subfield thickness (CST) reduction at Week 24. Seventy-three percent of DURAVYU 2.7 mg patients remained supplement-free through Week 24 versus 50% of aflibercept-treated patients in the control arm. The Phase 3 COMO and CAPRI clinical trials are fully enrolled with over 550 patients and topline data expected early in the fourth quarter of 2027.

R&D Updates:

DURAVYU (vorolanib intravitreal insert) 

Diabetic Macular Edema (DME)

• On July 30, 2026, we announced the pivotal Phase 3 COMO and CAPRI clinical trials completed enrollment, with a total of over 550 patients now enrolled in five months.
  • The identical non-inferiority trials versus an on-label aflibercept control include every six-month re-dosing and follow a clear and recognized regulatory approval pathway.
• Topline data for both DME trials are anticipated early in the fourth quarter of 2027.
  

Wet Age-Related Macular Degeneration (Wet AMD)

• On August 17, 2026, we announced the Phase 3 LUGANO trial did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept control in the full analysis population, despite demonstrating visual improvement.
  • DURAVYU achieved key secondary endpoints including a 42% reduction in treatment burden achieving superiority versus on-label aflibercept (nominal p-value of <0.0001), with 54% of eyes supplement-free and 79% receiving zero or one supplement up to Week 56, as well as strong anatomic control.
  • DURAVYU maintained a favorable safety profile with repeat dosing in patients. There were no observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, or retinal vasculitis.
• On October 19, 2026, we announced the Phase 3 LUCIA trial did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2mg aflibercept control in the full analysis population, despite demonstrating visual improvement.
  • DURAVYU achieved key secondary endpoints including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control, consistent with the first Phase 3 LUGANO clinical trial.
  • DURAVYU maintained a favorable safety profile with repeat dosing in patients. There were no observed occurrences of insert migration, anterior chamber opacities, free-floating drug particles, or retinal vasculitis.
• In a pooled analysis of the greater than 50% of patients in both trials who were supplement-free up to Week 56, DURAVYU was observed to be statistically non-inferior in mean change in BCVA versus on-label 2 mg aflibercept control.
• We will conclude the wet AMD program before completion of the full second year of the Phase 3 studies for both LUGANO and LUCIA, while also allowing additional patients to complete year two to support the necessary safety database for a potential new drug application for DME.
• We will complete additional analyses of both the LUGANO and LUCIA data along with the pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD.
  
  

Recent and Upcoming Presentations at Medical Conferences

• In July 2026, we delivered multiple oral presentations at the American Society of Retina Specialists (“ASRS”) Annual Meeting supporting DURAVYU’s potentially best-in-class therapeutic profile as a sustained release TKI being developed for multiple indications:
  • A characterization of the multi-mechanism of action of DURAVYU in retinal exudative diseases
  • Overview of key learnings from the Phase 2 DAVIO 2 clinical trial in wet AMD
  • Post-hoc analyses of patients from the Phase 2 DAVIO 2 clinical trial who met Phase 3 criteria
  • Overview of DME clinical program and key learnings: from the Phase 2 VERONA trial to pivotal Phase 3
• In September 2026, we delivered multiple presentations at the Retina Society Annual Meeting, underscoring the potential multi-modal activity of DURAVYU and enthusiasm from the retinal community for new treatment options in serious retinal diseases. This was the first conference where LUGANO data was presented to the retinal community.
  • Bioerodible EYP-1901 (vorolanib intravitreal insert) for Sustained Release of a Tyrosine Kinase Inhibitor for Retinal Exudative Disease
  • LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Vision and Anatomic Outcomes
  • LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Neovascular Age-Related Macular Degeneration: First-Time Safety and Treatment Burden Outcomes
  • Association Between Central Subfield Thickness Fluctuation and Visual Acuity Outcomes in Patients with Neovascular Age-Related Macular Degeneration: A Retrospective Analysis of the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight)
• In October 2026, we delivered multiple podium presentations and symposia at the 26th Euretina Congress, Innovate Retina, and the American Academy of Ophthalmology Annual Meeting (AAO 2026) providing additional detail on the LUGANO dataset, reviewing the mechanism of action and pharmacokinetic characteristics of DURAVYU for sustained release in retinal exudative disease, and reviewing key learnings from the prior Phase 2 studies DAVIO 2 in wet AMD and VERONA in DME.
  

Recent Corporate Updates

• Following the LUCIA results, our Board of Directors approved a strategic prioritization designed to extend our financial resources and focus on the late-stage DME program. The resulting approximately 53% workforce reduction, as well as associated operational adjustments, are expected to generate an estimated annualized savings of approximately $30 million.
  

“Capital discipline is now one of our highest priorities,” said George O. Elston, Executive Vice President and Chief Financial Officer. “Our objective is to preserve the resources required to obtain the pivotal DME data, while delivering COMO and CAPRI to the utmost standard. We have multiple levers available to us to further extend our financial runway and we intend to actively evaluate and pursue those opportunities to preserve strategic flexibility and maximize long-term shareholder value.”

Review of Results for the Third Quarter Ended September 30, 2026

For the quarter ended September 30, 2026, total net revenue was $0.8 million compared to $1.0 million for the corresponding period in 2025. Operating expenses for the quarter ended September 30, 2026, totaled $97.6 million versus $63.0 million for the corresponding period in 2025. This increase was primarily attributable to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME.

Net non-operating income totaled $1.3 million and net loss was $95.6 million, or ($1.07) per share, compared to a net loss of $59.7 million, or ($0.85) per share, for the corresponding period in 2025.

Cash, cash equivalents, and marketable securities as of September 30, 2026, totaled $118 million compared to $306 million as of December 31, 2025.

Financial Outlook

We expect the cash, cash equivalents, and marketable securities as of September 30, 2026, together with the additional $10 million of capital raised subsequent to quarter-end pursuant to our “at-the-market” equity facility and with anticipated operational adjustments, will enable us to fund operations into late third quarter of 2027. We continue to pursue business development, financing and other cost reduction opportunities that could further extend this cash runway.

Conference Call Information

EyePoint will host a conference call today at 8:30 a.m. ET to discuss the results for the third quarter ended September 30, 2026, and recent corporate developments. To access the live conference call, please register at https://edge.media-server.com/mmc/p/4ke9q689. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Forward Looking Statements

EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our cash runway; expectations regarding our strategic prioritization, including our workforce reduction, capital allocation strategy and estimated annual savings; our plans to conclude our Wet AMD program; expectations regarding our clinical development, regulatory and operational plans; our plans to complete additional analyses of the LUCIA and pooled Phase 3 datasets to further assess next steps for DURAVYU as a potential treatment for wet AMD; our expectations regarding DURAVYU’s potential to improve treatment outcomes for patients with wet AMD; our belief that the VERONA findings support DURAVYU’s therapeutic potential in DME; our belief that DURAVYU brings a potential new multi-mechanism of action and treatment paradigm for retinal diseases beyond existing anti-VEGF large molecule ligand blocking therapies; our expectations regarding the timing of the availability and release of DME clinical data, including topline results for Phase 3 COMO and CAPRI clinical trials in DME early in the fourth quarter of 2027; and other statements regarding the Company’s future plans, objectives, strategies and beliefs, as identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” or other words of similar meaning or the use of future dates.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the Company’s clinical development activities; uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval from FDA for the commercialization of DURAVYU; unanticipated costs and expenses; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; uncertainties regarding the Company’s ability to continue as a going concern; the Company may incur additional costs in connection with its strategic prioritization not currently contemplated; the Company’s ability to use business development, financing activities or other operational savings and adjustments to extend its cash runway; the Company’s ability to comply with Nasdaq’s minimum bid compliance requirement; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the Company’s product candidates; changes in the regulatory environment; disruptions at the FDA; changes in U.S. and international trade policies; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates, including due to unanticipated regulatory compliance issues or warning letters relating to the Company’s manufacturing facilities; the availability of and the need for additional financing; our ability to obtain additional funding to support our clinical development programs; uncertainties regarding the FDA warning letter pertaining to the Company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. A more complete discussion of the risks and uncertainties that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, in our other filings with the Securities and Exchange Commission (SEC) and in our future reports to be filed with the SEC, which are available at www.sec.gov. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors & Media:

Robin Garner
VP, Corporate Communications & Investor Relations
ir@eyepoint.bio

EYEPOINT, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands)
		September 30,				December 31,
		2026				2025
Assets
Current assets:
Cash and cash equivalents		$	83,206			$	101,821
Marketable securities			35,007				204,265
Accounts and other receivables, net			259				651
Prepaid expenses and other current assets			6,849				20,105
Inventory			1,665				1,813
Total current assets			126,986				328,655
Operating lease right-of-use assets			19,288				20,223
Other assets			19,863				15,118
Total assets		$	166,137			$	363,996
Liabilities and stockholders' equity
Current liabilities:
Accounts payable and accrued expenses		$	35,757			$	34,884
Other current liabilities			2,750				2,140
Total current liabilities			38,507				37,024
Operating lease liabilities - noncurrent			19,124				20,772
Other noncurrent liabilities			-				87
Total liabilities			57,631				57,883
Stockholders' equity:
Capital			1,487,584				1,410,130
Accumulated deficit			(1,379,892	)			(1,104,978	)
Accumulated other comprehensive income			814				961
Total stockholders' equity			108,506				306,113
Total liabilities and stockholders' equity		$	166,137			$	363,996

EYEPOINT, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data)
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Revenues:
Product sales, net		$	528			$	582			$	995			$	1,297
License and collaboration agreements			49				150				695				16,531
Royalty income			179				234				269				12,923
Total revenues			756				966				1,959				30,751
Operating expenses:
Cost of sales			523				721				1,056				1,691
Research and development			81,670				47,754				237,427				161,825
Sales and marketing			31				26				65				96
General and administrative			15,409				14,490				44,894				40,228
Total operating expenses			97,633				62,991				283,442				203,840
Loss from operations			(96,877	)			(62,025	)			(281,483	)			(173,089	)
Other income (expense):
Interest and other income, net			1,265				2,293				6,519				8,829
Total other income, net			1,265				2,293				6,519				8,829
Net loss before provision for income taxes		$	(95,612	)		$	(59,732	)		$	(274,964	)		$	(164,260	)
Provision for income taxes			—				—				50				(93	)
Net loss		$	(95,612	)		$	(59,732	)		$	(274,914	)		$	(164,353	)
Net loss per common share - basic and diluted		$	(1.07	)		$	(0.85	)		$	(3.15	)		$	(2.35	)
Weighted average common shares outstanding - basic and diluted			89,245				70,168				87,274				69,955

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does EyePoint expect Phase 3 DURAVYU DME results?

EyePoint anticipates topline results from COMO and CAPRI early in the fourth quarter of 2027. The trials are fully enrolled with over 550 patients. Both compare DURAVYU with on-label aflibercept and include redosing every six months.

How long does EyePoint expect its cash to fund operations?

EyePoint expects funding to support operations into late third quarter of 2027. That outlook includes cash, cash equivalents and marketable securities at September 30, 2026, an additional $10 million raised after quarter-end through its at-the-market equity facility, and anticipated operational adjustments.

What further work does EyePoint plan on DURAVYU wet AMD data?

EyePoint plans additional analyses of LUGANO, LUCIA and pooled Phase 3 datasets to assess next steps for DURAVYU as a potential wet AMD treatment. The company also intends to let additional patients complete year two to support the safety database for a potential DME new drug application.